# A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Source: https://onco.cc/trials/nct07287098/  
OnCo record `nct07287098` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Imlunestrant and Tamoxifen in HR-positive / HER2-negative breast cancer, run by Eli Lilly and Company, now recruiting.

## Summary

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer is a phase 2 interventional study registered as NCT07287098 by Eli Lilly and Company, with 600 participants planned, started 2026-05-13 and due to reach its primary completion in 2029-01. Interventions recorded: Imlunestrant, Goserelin and Tamoxifen 20 mg.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07287098
- Phase: 2
- Setting: preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer
- Sponsor: Eli Lilly and Company
- Enrolled: 600

## Sources

- ClinicalTrials.gov NCT07287098: https://clinicaltrials.gov/study/NCT07287098

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Imlunestrant](https://onco.cc/drugs/imlunestrant/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct07287098.json